1927-nm thulium laser: Fractional non-ablative 1927-nm thulium laser treatment applied to the randomized intervention side of the face
1550-nm Er:Glass laser: Fractional non-ablative 1550-nm Er:Glass laser treatment applied to the randomized intervention side of the face
Intense Pulsed Light: Intense pulsed light treatment applied to the randomized intervention side of the face
Study summary
The Multimodal Laser Project is a prospective, randomized, split-face clinical study investigating a novel combination of laser and light-based treatments for facial photodamage with the long-term perspective of improving skin cancer prevention.
The study includes 35 patients with facial photodamage and AKs. One side of the face receives a multimodal treatment combining three complementary technologies: 1927-nm thulium laser, 1550-nm non-ablative fractional laser, and intense pulsed light (IPL), while the contralateral side serves as an untreated control.
Participants are followed for 14 months to assess both clinical efficacy and longer-term preventive effects.
The overall aim is not only to determine whether multimodal laser treatment improves photodamaged skin, but also to gain a deeper understanding of how the treatment affects the underlying biology of chronically sun-damaged skin and its potential role in skin cancer prevention.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years
* Clinical signs of facial photodamage, including low-grade actinic keratosis (Olsen grade I-II) , solar lentigines, mottled hyper- and hypopigmentation, telangiectasia, skin thinning or atrophy, loss of skin elasticity (solar elastosis), coarse, leathery texture
Exclusion Criteria:
* Fitzpatrick skin type ≥ 4
* Active skin disease in the treatment area that may interfere with study treatment or assessments
* Cosmetic treatments in the face within the last 12 months, including but not limited to chemical peels, injectables, and light- or laser-based treatments
* Pregnancy or breastfeeding
* Contraindications to the three lasers or topical anesthetics
* Fitzpatrick skin type ≥ 4
* Active skin disease in the treatment area that may interfere with study treatment or assessments
* Cosmetic treatments in the face within the last 12 months, including but not limited to chemical peels, injectables, and light- or laser-based treatments
* Pregnancy or breastfeeding
* Contraindications to the three lasers or topical anesthetics
Primary outcome measure(s)
Clinical improvement — Baseline to Week 60 Change from baseline in the overall clinical appearance of facial photodamage will be assessed using a 5-point Global Aesthetic Improvement Scale (GAIS) based on standardized clinical photographs and on-site evaluation. Assessments will be performed by the site investigator and independent blinded physicians. The scale ranges from 1 to 5, where 1 = very much improved and 5 = worse. Lower scores indicate greater clinical improvement.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.